MIRACLE SCIENCE INNOVATION Co., Ltd. (Headquarters: Kita-ku, Osaka City; President: Jun Miyakawa; hereinafter: MIRACLE SI) announces the selection of three programs—the "NQ Health Accelerator Program," the "NQ Edition COO Talent Development Program," and the "NQ Edition Bio-Catalyst AI Accelerator Program"—by the Osaka Prefecture "NQ Global Startup Gateway (Nakanoshima Cross Global Startup Creation and Hub Promotion Project Commissioned Work)." This project is undertaken by the "NQ Global Startup Gateway Consortium※1※2," a consortium of six companies with MIRACLE SI as the lead organization. the "NQ COO Talent Development Program," and the "NQ Bio-Catalyst AI Accelerator Program."
※1 NQ Global Startup Gateway Joint Venture
・MIRACLE SCIENCE INNOVATION Co., Ltd. (Lead Organization) (Kita-ku, Osaka City; President and CEO: Jun Miyakawa)
・AstraZeneca K.K. (Osaka City, Kita Ward; Director, Innovation Partnerships & i2.JP, Insights & Business Excellence Division; Lei Liu)
・Cambridge Consultants Inc. (Minato-ku, Tokyo; President and CEO: Yoichi Ishige)
・MedTech Actuator LLC (Osaka City, Kita Ward, Japan; General Manager: Junichi Higashi)
・ALLOY THERAPEUTICS Co., Ltd. (Fujisawa City, Kanagawa Prefecture; President and CEO: Yoshihide Ishii)
・Deep Intelligent Pharma Co., Ltd. (Chuo-ku, Tokyo; President: Li Xing)
※2 NQ = Nakanoshima Qross
Osaka Prefecture "NQ Global Startup Gateway (Nakanoshima Cross Global Startup Creation and Hub Promotion Project Commissioned Work)"
The Osaka Prefecture Initiative is a life sciences startup cluster and incubation program aimed at establishing a world-class startup ecosystem and fostering globally competitive startups. To solidify the position of Nakanoshima Qross, the Future Medical International Hub in Osaka's Nakanoshima district, as a hub for industrializing future medicine—including regenerative medicine—it will enhance its capabilities for clustering and nurturing life sciences startups, the driving force behind this endeavor.
The following three programs have now selected their recipients.
■Global Startup Creation Support Program (Fiscal Years 2025 and 2026)
NQ Health Accelerator Program
Creating global startups through the provision of tailor-made startup support programs and overseas travel support programs. AstraZeneca, Cambridge Consultants, and MedTech Actuator collaborate on this program focused on overseas market development.
Following the open call and review process, the following 16 companies were selected.
| No | Name of Adopting Entity (Company) | Business Overview |
| 1 | Qualyps Inc. | Development and Commercialization of Human iPS Cell-Derived Cardiomyocyte Sheets |
| 2 | LinkMed Co., Ltd. | Development of a Visualizable Cancer Therapeutic Using Radioisotope Copper-64 (⁶⁴Cu) |
| 3 | Ixforest Co., Ltd. Therapeutics | RNA Targeted Small Molecule Drug Discovery Platform and In-House Drug Discovery Business |
| 4 | PhysioLogic Technologies, Inc. | Development of a Home Hemodialysis System Requiring No Water Supply |
| 5 | Quadritics Inc. | Development of a medical device called the "Epilepsy Alarm" that predicts epileptic seizures using wearable technology and alerts patients and caregivers |
| 6 | Lead Pharma Co., Ltd. | Based on our proprietary "BROTHERS technology," we are developing innovative nucleic acid therapeutics that achieve both safety and efficacy. |
| 7 | PaMeLa Inc. | Development of the PMS-2 Medical Device for Objectively Assessing Pain Using Brain Waves and AI |
| 8 | Immunocense Inc. | Development and sales of POCT devices utilizing proprietary GLEIA technology |
| 9 | ayumo Inc. | Development of medical devices capable of supporting early diagnosis of musculoskeletal disorders utilizing computer vision, and Development of wellness services that contribute to the evaluation, maintenance, and improvement of motor function |
| 10 | NeoCure Co., Ltd. | Providing AI to eliminate childhood blindness caused by retinopathy of prematurity |
| 11 | Arktus Therapeutics, Inc. | Development of Artificial Joints Using iPS Cell-Derived Cartilage |
| 12 | At Corporation | Developing a capillary index platform business centered on non-invasive capillary scopes and image analysis technology |
| 13 | GramEye Inc. | Development and Sales of Mycrium® Automated Gram Staining Medical Device and Microbial Identification AI Platform |
| 14 | Cellfold Co., Ltd. | Commercialization of cell therapy and regenerative medicine utilizing the injectable cell scaffold (ICS) as core technology |
| 15 | SONoALS Inc. | A medical device integrating wearable ultrasound and AI for muscle twitch analysis, aimed at ultra-early diagnosis of ALS and drug efficacy evaluation systems |
| 16 | nonat Inc. | Research and Development of a Medical AI Platform Model Specialized for Women and Children |
Onboarding sessions were held on Tuesday, December 23, 2025, at the Qrossover Lounge Yume on the 2nd floor of Nakanoshima Qross. From Monday, January 26, 2026, to Wednesday, January 28, 2026, we will conduct an intensive program to strengthen Global Readiness※3, featuring domestic and international experts as instructors.
Program Details:https://nq-gateway.jp/programs
※3 "Global Readiness" refers to the ability and mindset of individuals and organizations to operate effectively in cross-border business and international environments, adapting to diverse cultures and change.
■Startup Support Enhancement Project (Fiscal Year 2025)
(1) Nakanoshima Qross COO Talent Development Program
This is the first program in Japan specifically designed to cultivate COO talent for startups.
We have selected individuals with diverse backgrounds, including pharmaceutical companies, medical device companies, general trading companies, physicians, financial institutions, and consultants.
The first intensive session will be held over two days: Friday, December 26, 2025, and Saturday, December 27, 2025.
The intensive sessions included onboarding sessions, as well as lectures by Mr. Taku Serio (Representative Director, Development Capability Promotion Organization (DDCP)), Ms. Tomoko Maeda (Head of R&D Alliance, Kobe Pharmaceutical Research Institute, Boehringer Ingelheim Japan Co., Ltd.), and Mr. Yoshitsugu Shitaka (President and CEO, RealizeEdge Partners Co., Ltd.). Through participant roundtables and team projects, we will conduct an intensive session titled "From Science to Patients: From Academia to Ventures, From Pharmaceutical Companies to Society." Moving forward, intensive sessions incorporating case methods to encourage discussion among participants, including online work at the midpoint, will be held in January and February.
(2) NQ Edition Bio-Catalyst AI Accelerator Program
This program leverages Deep Intelligent Pharma’s cutting-edge AI and global domain expertise to transform promising startups into investor-ready companies.
Following the open call and review process, the following 11 companies have been selected.
| No | Affiliation/Organization Name | Position, etc. | Name | Content |
|---|---|---|---|---|
| 1 | MEDICOLAB Co., Ltd. | President and CEO | Kazuhiro Igumi | Programmed Medical Devices for Early Detection of Parkinson's Disease and Dementia |
| 2 | Eudaimonix Inc. | President and CEO | Ryotaro Tani | Device development to address challenges faced by ostomy patients and those with fecal incontinence |
| 3 | PurinoScience Inc. (Pre-incorporation) | Co-founder and Chief Strategy Officer | Ken Okamoto | Development of Oral Therapeutics for Age-Related Decline in Muscle Strength and Mobility |
| 4 | Osaka Medical and Pharmaceutical University Emergency Medicine | Associate Professor | Kazuma Yamakawa | Development of a Clinical Decision Support System Bridging Clinical Practice Guidelines and Frontline Care |
| 5 | Osaka University Graduate School of Medicine Endocrinology and Metabolic Medicine Lifestyle Medicine Endowed Chair | Associate Professor (Endowed Chair) | Megumi Udon | Development of a Diabetes Personalized Treatment Support App Based on the Japanese Version of Teaching Kitchen |
| 6 | Graduate School of Medicine, Osaka University Immune Cell Biology | Special Researcher | Hiroshi Abe | Development of a Wide-Area Biopsy and Ultra-Rapid Intraoperative Diagnosis Method Using Multiphoton Excitation Microscopy |
| 7 | Osaka University of Health and Medical Sciences／ Osaka University | Principal Researcher Professor / Visiting Professor | Nakamura Norimasa | Treatment of Refractory Knee Meniscus Injuries Using Allogeneic Mesenchymal Stem Cell-Derived Three-Dimensional Artificial Tissue (TEC) Practical Application of Regenerative Therapy Technologies |
| 8 | Kansai Medical University School of Medicine Physiology Course | Instructor | Miki Hayashi | Development of a Novel Oral Anticancer Agent Targeting Cancer Stem Cells |
| 9 | Kyoto University iCeMS | Designated Researcher | Naoto Kinashi | Development of the World's First Implantation-Promoting Drug Based on the Mechanism of Integrin Activation |
| 10 | National Cardiovascular Center Cardiovascular Medicine Department Coronary Disease Division | Chief Physician | Takagi Kento | Development of Next-Generation Navigation AI Guiding Accurate and Burden-Free Cardiac Catheterization Procedures Using Only Contrast Images |
| 11 | Hyogo College of Medicine／ Midori-ga-Oka Hospital Rehabilitation Department | Part-time Lecturer / Department Head | Shinichi Nakagawa | Development of an Ordering and Dispatch Process for Medical Devices Utilizing AI Technology |
Following the onboarding session held on December 5, we provide a program that transforms promising seed startups into investable companies. This is achieved through support in formulating business strategies, intellectual property strategies, regulatory strategies, non-clinical trial plans, and clinical plans utilizing Deep Intelligent Pharma's cutting-edge AI technology, combined with three intensive mentoring sessions leveraging global industry expertise.
The selected participants for the three programs—"NQ Health Accelerator Program," "NQ COO Talent Development Program," and "NQ Bio-Catalyst AI Accelerator Program"—have been determined. Moving forward, the organizers—Osaka Prefecture and the NQ Global Startup Gateway consortium—will provide these selected participants with intensive, dedicated support through NQ's unique special programs. Additionally, by facilitating network building with overseas ecosystem organizations and other entities, we will help them achieve global expansion.
Furthermore, through this initiative, we will solidify NQ's position as a hub for future medical industrialization and build a brand reputation that "businesses can be rapidly and reliably commercialized at NQ." To achieve this, we will attract promising life science startups from both domestic and international markets. We will provide thorough, dedicated support through NQ's unique special programs and build networks with overseas ecosystem organizations and related institutions.